Harvard Bioscience Inc
$ 6.48
-0.31%
04 Jun - close price
- Market Cap 29,226,000 USD
- Current Price $ 6.48
- High / Low $ 6.55 / 6.21
- Stock P/E N/A
- Book Value 2.25
- EPS -2.15
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.79 %
- 52 Week High 9.40
- 52 Week Low 3.75
About
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Analyst Target Price
$6.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-12 | 2025-11-06 | 2025-08-11 | 2025-05-12 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-07 | 2024-03-07 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.77 | -0.6383 | -0.03 | -0.1 | -0.1 | 0.06 | -0.2 | -0.0673 | 0.2 | 0.04 | 0.1 | 0.4 |
| Estimated EPS | -0.95 | 0.04 | 0.05 | -0.25 | -0.4 | 0.05 | 0.15 | 0.5 | 0.25 | 0.05 | 0.4 | 0.55 |
| Surprise | 0.18 | -0.6783 | -0.08 | 0.15 | 0.3 | 0.01 | -0.35 | -0.5673 | -0.05 | -0.01 | -0.3 | -0.15 |
| Surprise Percentage | 18.9474% | -1695.75% | -160% | 60% | 75% | 20% | -233.3333% | -113.46% | -20% | -20% | -75% | -27.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.21 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.2832258065 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HBIO
2026-06-03 03:10:21
This article is a placeholder indicating that Harvard Bioscience announced its First Quarter 2026 Financial Results via an 8-K filing. The content displayed is merely a document placeholder, suggesting the detailed results would be within the actual 8-K filing.
2026-06-02 20:09:46
Harvard Bioscience, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including an increase of 400,000 shares for their 2021 Incentive Plan and amendments to the Employee Stock Purchase Plan. Shareholders also re-elected two Class II directors, ratified Grant Thornton LLP as the independent auditor, and gave a non-binding advisory vote in favor of executive compensation. These actions reflect significant governance decisions and adjustments to employee equity programs for the coming years.
2026-06-01 01:39:44
This article reports that the price target for Harvard Bioscience (HBIO) has been significantly increased by 200.00% to $6.12. No further details are provided in the snippet.
2026-05-25 00:40:21
Harvard Bioscience Inc (HBIO) is currently considered to be in the "Fair zone," with its forward PE ratio of 15.06 fairly comparable to its five-year average of 23.52. The fair price for HBIO is estimated to be between $2.40 and $14.02 based on a relative valuation method. While its current P/B ratio and FCF yield show some deviations from historical averages, its P/S ratio of 0.27 is significantly above the industry average, which the analysis suggests might be unsustainable given its revenue growth of -4.68%.
2026-05-21 12:10:11
Harvard Bioscience (HBIO) reported mixed results for Q2 2025, with revenue missing estimates but adjusted earnings matching expectations thanks to improved cash flow and cost control. The company, a small-cap medtech supplier, operates in the life sciences research sector, making its performance sensitive to research spending cycles and capital expenditures by labs and institutions. Investors are watching to see if management can stabilize demand and convert cost control into sustained operating improvement amidst ongoing market volatility.
2026-05-16 00:09:11
Harvard Bioscience, Inc. (NASDAQ:HBIO) published its Q1 2026 earnings call presentation, reporting an EPS of -$0.33, missing estimates by $0.30, and revenue of $20.76M, a 4.68% year-over-year decrease, missing by $445.00K. The article highlights that the slide deck was released in conjunction with their earnings call.
